Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
Expert Opin Investig Drugs. 2010 Jan;19(1):105-15. doi: 10.1517/13543780903438559.
TNF antagonists have become an integral part of the standard of care for patients with rheumatoid arthritis (RA). Two additional TNF antagonists have recently been approved in the US for this indication, and clinicians will need to understand the data on the efficacy and safety of these agents in order to properly place them into the clinical treatment algorithm.
This review covers the published clinical trial data on the use of certolizumab and golimumab for RA. The literature search included manuscripts published through September 2009 and abstracts from major meetings (ACR and EULAR) in 2007 - 2009.
This paper will review the efficacy and safety of golimumab and certolizumab in the treatment of RA at various stages of disease. Use of these agents will be described in the context of other available alternatives, including other TNF antagonists and other biologic therapies.
Certolizumab and golimumab have comparable efficacy and safety profiles compared with previously approved TNF antagonists. These two agents have several unique theoretical benefits when compared to existing agents, but the available published data do not suggest a clear clinical advantage at this time.
肿瘤坏死因子（TNF）拮抗剂已成为类风湿关节炎（RA）患者标准治疗的一个组成部分。最近，另外两种 TNF 拮抗剂已在美国获得批准用于这一适应证，为了将这些药物恰当地纳入临床治疗方案，临床医生需要了解这些药物在疗效和安全性方面的数据。
这篇综述涵盖了已发表的关于依那西普和戈利木单抗治疗 RA 的临床试验数据。文献检索包括截至 2009 年 9 月发表的论文和 2007-2009 年主要会议（ACR 和 EULAR）的摘要。
本文将综述戈利木单抗和依那西普在疾病不同阶段治疗 RA 的疗效和安全性。将根据其他可用替代药物（包括其他 TNF 拮抗剂和其他生物制剂）来描述这些药物的应用。
依那西普和戈利木单抗与已批准的 TNF 拮抗剂具有可比的疗效和安全性。与现有的药物相比，这两种药物具有一些独特的理论优势，但目前可用的已发表数据并未表明其具有明显的临床优势。
